Search

Your search keyword '"Ng, Hoi-Yan"' showing total 23 results
Start Over Author "Ng, Hoi-Yan"
23 results on '"Ng, Hoi-Yan"'

1. Multigene Profiling of Circulating Tumor Cells in Esophageal Squamous Cell Carcinoma Identifies Prognostic Cancer Driver Genes Associated with Epithelial-Mesenchymal-Transition Progression and Chemoresistance

Author

Tan, Zhen, primary, Ko, Josephine Mun-Yee, additional, Yu, Valen Zhuoyou, additional, Lam, Ka-On, additional, Kwong, Dora Lai-Wan, additional, Wong, Ian Yu-Hong, additional, Chan, Fion Siu-Yin, additional, Wong, Claudia Lai-Yin, additional, Chan, Kwan-Kit, additional, Law, Tsz-Ting, additional, Choy, Faith Sin-Fai, additional, Ng, Hoi-Yan, additional, Law, Simon Ying-Kit, additional, and Lung, Maria Li, additional

Published
2023
Full Text
View/download PDF

2. Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry.

Author

Mok, Chi Chiu, So, Ho, Yim, Cheuk Wan, To, Chi Hung, Lao, Weng Nga, Wong, Stella Pui Yan, Ng, Hoi Yan, Lee, Jolly Man Yee, Lee, Patrick Man Leung, Ying, Shirley King Yee, Leung, Moon Ho, and Ho, Carmen Tze Kwan

Subjects
CONFIDENCE intervals, MAJOR adverse cardiovascular events, ANTI-inflammatory agents, RETROSPECTIVE studies, DISEASE incidence, INFECTION, JANUS kinases, RISK assessment, COMPARATIVE studies, RHEUMATOID arthritis, DESCRIPTIVE statistics, HERPES zoster, RESEARCH funding, TUMORS, NEUROTRANSMITTER uptake inhibitors, PATIENT safety
Abstract

Objectives To compare the incidence of major adverse cardiovascular events (MACEs), cancer and infective complications in RA patients using Janus kinase (JAKis) and TNF (TNFis) inhibitors. Method A retrospective analysis of data from the Hong Kong Biologics Registry 2008–2021 was performed. RA patients who had ever used JAKis or TNFis were included. The incidence of MACEs, cancer and infections were compared between the two groups, with adjustment for confounding factors. Results A total of 2471 courses of JAKis (n  = 551) and TNFis (n  = 1920) were used in 1732 RA patients (83.7% women, age 53.8 [12.5] years; follow-up 6431 patient-years). JAKi users had significantly older age, more atherosclerotic risk factors and higher frequency of past malignancies. A total of 15 and 40 MACEs developed in the JAKi and TNFi users, respectively (incidence 1.34 vs 0.75 per 100 patient-years; P  = 0.22). There was no significant difference in the incidence of cancers between the two groups (0.81 [JAKi] vs 0.85 [TNFi] per 100 patient-years; P  = 0.25). The adjusted hazard ratios of MACE and cancer in the JAKi users were 1.36 (95% CI: 0.62, 2.96) (P  = 0.44) and 0.87 (95% CI: 0.39, 1.95) (P  = 0.74), respectively. Rates of infections were significantly higher in the JAKi than TNFi users (16.3 vs 9.9 per 100 patient-years; P  = 0.02), particularly herpes zoster (3.49 vs 0.94 per 100 patient-years; P  < 0.001). Conclusions In a real-life setting, there is no increase in MACEs or cancers in users of JAKis compared with TNFis. However, the incidence of non-serious infections, including herpes zoster, was increased in users of JAKis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma

Author

Ng, Hoi Yan, primary, Ko, Josephine Mun Yee, additional, Lam, Ka On, additional, Kwong, Dora Lai Wan, additional, Lo, Anthony Wing Ip, additional, Wong, Ian Yu Hong, additional, Wong, Claudia Lai Yin, additional, Chan, Siu Yin, additional, Chan, Kwan Kit, additional, Law, Tsz Ting, additional, Dai, Wei, additional, Fong, Henry Chun Hung, additional, Choy, Faith Sin Fai, additional, Lo, Chun Kit, additional, Chen, Cancan, additional, Law, Simon Ying Kit, additional, and Lung, Maria Li, additional

Published
2023
Full Text
View/download PDF

4. Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry

Author

Mok, Chi Chiu, primary, So, Ho, additional, Yim, Cheuk Wan, additional, To, Chi Hung, additional, Lao, Weng Nga, additional, Wong, Stella Pui Yan, additional, Ng, Hoi Yan, additional, Lee, Jolly Man Yee, additional, Lee, Patrick Man Leung, additional, Ying, Shirley King Yee, additional, Leung, Moon Ho, additional, and Ho, Carmen Tze Kwan, additional

Published
2023
Full Text
View/download PDF

5. Nasopharyngeal carcinoma MHC region deep sequencing identifies HLA and novel non-HLA TRIM31 and TRIM39 loci

Author

Ning, Lvwen, Ko, Josephine Mun-Yee, Yu, Valen Zhuoyou, Ng, Hoi Yan, Chan, Candy King-Chi, Tao, Lihua, Lam, Shiu-Yeung, Leong, Merrin Man-Long, Ngan, Roger Kai-Cheong, Kwong, Dora Lai-Wan, Lee, Anne Wing-Mui, Ng, Wai-Tong, Cheng, Ashley, Tung, Stewart, Lee, Victor Ho-Fun, Lam, Ka-On, Kwan, Chung-Kong, Li, Wing-Sum, Yau, Stephen, Bei, Jin-Xin, and Lung, Maria Li

Published
2020
Full Text
View/download PDF

9. 245. CLINICAL UTILITY OF CTDNA IN LONGITUDINAL MONITORING OF TREATMENT RESPONSES AND RELAPSE IN METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA

Author

Ng, Hoi Yan, primary, Ko, Josephine, additional, Wong, Ian Yu Hong, additional, Wong, Claudia Lai Ying, additional, Chan, Siu Yin, additional, Chan, Kwan Kit, additional, Law, Tsz Ting, additional, Lam, Ka On, additional, Kwong, Dora Lai Wan, additional, Law, Simon Ying Kit, additional, and Lung, Maria Li, additional

Published
2022
Full Text
View/download PDF

12. Liquid Biopsy Serial Monitoring of Treatment Responses and Relapse in Advanced Esophageal Squamous Cell Carcinoma

Author

Ko, Josephine Mun Yee, primary, Ng, Hoi Yan, additional, Lam, Ka On, additional, Chiu, Keith Wan Hang, additional, Kwong, Dora Lai Wan, additional, Lo, Anthony Wing Ip, additional, Wong, Jean Chrysei, additional, Lin, Roger Chia Wei, additional, Fong, Henry Chun Hung, additional, Li, Jason Ying Ki, additional, Dai, Wei, additional, Law, Simon, additional, and Lung, Maria Li, additional

Published
2020
Full Text
View/download PDF

14. Therapeutic Drug Monitoring in Rheumatic Diseases

Author

Chi Chiu Mok and Alexandra Ng Hoi-Yan

Subjects
medicine.medical_specialty, hydroxychloroquine, medicine.diagnostic_test, business.industry, therapeutic drug monitoring, mycophenolate mofetil, RC581-607, Rheumatology, Therapeutic drug monitoring, Internal medicine, tacrolimus and tnf inhibitors, Medicine, Immunologic diseases. Allergy, business, Intensive care medicine
Abstract

The ultimate goal of treating rheumatic disease is to achieve rapid suppression of inflammation, while at the same time minimizing the toxicities from rheumatic drugs. Different patients have different individual pharmacokinetics that can affect the drug level. Moreover, different factors, such as renal function, age or even different underlying diseases, can affect the drug level. Therefore, giving the same dosage of drugs to different patients may result in different drug levels. This article will review the usefulness of therapeutic drug monitoring in maximizing drug efficacy, while reducing the risk of toxicities in Hydroxychloroquine, Mycophenolate Mofetil, Tacrolimus and Tumor Necrosis Factor inhibitors (TNF Inhibitors).

Published
2016

17. Risk of community-acquired pneumonia requiring hospitalization in patients with spondyloarthritis.

Author

Chung, Ho Yin, Tam, Lai Shan, Chan, Shirley Chiu Wai, Cheung, Jason Pui Yin, Wong, Pui Yan, Ciang, Chu Oi, Ng, Hoi Yan, Law, Mei Yan, Lai, Tin Lok, and Wong, Ching Han

Abstract

Aims: To compare the risk of community-acquired pneumonia (CAP) requiring hospitalization in spondyloarthritis (SpA) and non-specific back pain (NSBP), and to identify the risk factors for CAP in SpA. Methods: A total of 2984 patients with SpA from 11 rheumatology centers and 2526 patients with NSBP from orthopedic units were reviewed from the centralized electronic database in Hong Kong. Incidence of CAP requiring hospitalization and demographic data including age, gender, smoking and drinking status, use of sulfasalazine, individual biological-disease modifying anti-rheumatic drugs (DMARDs) used, micro-organisms, other immunosuppressants or immunosuppressive states, use of steroid for more than ½ year, and co-morbidities were identified. Risks of CAP in SpA were compared with those in NSBP using propensity score regression method. Multivariate Cox regression model was used to identify the risk factors in SpA. Results: CAP requiring hospitalization was found in 183 patients with SpA and 138 patients with NSBP. Increased risk for CAP was found in the following groups with SpA: all subgroups (hazard ratio (HR) 2.14, p < 0.001), without use of DMARDs (HR 2.64, p < 0.001), without psoriasis and not taking DMARDs (HR 2.38, p < 0.001). Infliximab (HR2.55, p = 0.04), smoking (HR 1.68, p = 0.003), comorbid psoriasis (HR 1.67, p = 0.003), and use of steroid for more than ½ year (HR 1.94, p = 0.003) were found to associate with CAP after adjustments for traditional risk factors. Conclusion: Risk of CAP is increased in patients with SpA. Our data favor universal influenza and pneumococcal vaccination programs in the population. Rheumatologists should also advise smoking cessation and avoid long term steroid therapy. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results